Jessica Cutler
Family · Glens Falls, NYNPI 1053046037
Payments from drug & device makers
Across 314 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$817
- Lilly USA, LLC$641
- GSK$612
- AstraZeneca$424
- Axsome Therapeutics, Inc.$358
- plus $2K from 23 others
What the payments were for
- Food & beverage$6,69397%
- Education$2223%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 83 | $1,608 |
| AbbVie | 38 | $817 |
| Lilly USA, LLC | 34 | $641 |
| GSK | 27 | $612 |
| AstraZeneca | 23 | $424 |
| Axsome Therapeutics, Inc. | 5 | $358 |
| Otsuka America Pharmaceutical, Inc. | 14 | $326 |
| Astellas Pharma US Inc | 8 | $287 |
| Pfizer | 18 | $284 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $247 |
| Amgen | 11 | $202 |
| E.r. Squibb & Sons, L.L.C. | 3 | $178 |
| Idorsia Pharmaceuticals US Inc | 5 | $105 |
| Amneal Pharmaceuticals LLC | 5 | $98 |
| Seagen Inc. | 1 | $95 |
| Abbott | 4 | $79 |
| Neurocrine Biosciences, Inc. | 2 | $78 |
| Boston Scientific | 4 | $78 |
| Boehringer Ingelheim | 4 | $68 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $67 |
| Johnson & Johnson | 3 | $62 |
| Sumitomo Pharma America, Inc. | 3 | $55 |
| Vertex | 2 | $41 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Bayer | 1 | $19 |
| Indivior Inc. | 1 | $19 |
| Insulet Corporation | 1 | $15 |
| Renalytix AI, Inc. | 1 | $14 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,915 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 46 | $57,038 |
| EliquisApixaban | 15 | $19,629 |
| MounjaroTirzepatide | 16 | $18,726 |
| JardianceEmpagliflozin | 26 | $18,043 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $10,874 |
| MyrbetriqMirabegron | 15 | $6,884 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $5,276 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 46 | $1,802 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $1,424 |
| Levothyroxine Sodium | 100 | $1,125 |
| Omeprazole | 82 | $1,069 |
| Atorvastatin Calcium | 118 | $903 |
| Rosuvastatin Calcium | 46 | $691 |
| Lisinopril | 81 | $642 |
| Gabapentin | 31 | $537 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,608 | $57,03846 claims |
| PfizerEliquis | $284 | $19,62915 claims |
| Lilly USA, LLCMounjaro | $641 | $18,72616 claims |
| Boehringer IngelheimJardiance | $68 | $18,04326 claims |
| GSKTrelegy Ellipta | $612 | $10,87417 claims |
| Astellas Pharma US IncMyrbetriq | $287 | $6,88415 claims |
| AstraZenecaSymbicort | $424 | $5,27612 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $98 | $1,125100 claims |
| AbbVieSynthroid | $817 | $41312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.
Other family in Glens Falls
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.